Navigation Links
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Date:5/27/2008

Study finds a trend toward better overall survival

TUESDAY, May 27 (HealthDay News) -- Adding paclitaxel to standard chemotherapy improved disease-free survival in women with early-stage breast cancer, a Spanish study finds.

The phase III trial included 1,246 women with early, non-metastatic breast cancer who were randomly assigned to receive treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC), or FEC followed by weekly paclitaxel (FEC-P).

The estimated five-year survival rate in the FEC-P group was 78.5 percent, compared to 72.1 percent in the FEC group. The study also found a trend toward improved overall survival, but it didn't reach statistical significance.

"Because distant relapse-free survival is usually associated with overall survival, a statistically significant benefit in overall survival may become evident with a more protracted follow-up," wrote Dr. Miguel Martin, of the Spanish Breast Cancer Research Group.

In a retrospective analysis of the data, the researchers weren't able to identify a subgroup of patients who were more likely to respond to paclitaxel therapy on the basis of their tumor's expression of the estrogen receptor and HER2.

The study was published in the May 27 online issue of the Journal of the National Cancer Institute.

In an accompanying editorial, researchers at Memorial Sloan-Kettering Cancer Center in New York City reviewed several trials that examined the effects of adding taxanes (a family of drugs that include paclitaxel) to existing adjuvant therapy for breast cancer.

In that regard, the study by the Spanish team is important, because it was well-designed and used a good regimen and schedule of drugs, noted Dr. Clifford Hudis and Dr. Chau Dang.

More information

The National Cancer Institute has more about breast cancer treatment.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, May 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
9. Medicare modernization act did not change chemotherapy as feared
10. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
11. Cancer conflict with chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... , ... In any business, follow up is critical to success. It is ... presenting treatment, there will always be some patients who can’t or won’t make a ... practices when it comes to presenting treatment. After the patient leaves, most practices ...
(Date:5/26/2017)... YORK, NY (PRWEB) , ... May 26, 2017 ... ... Board (SAB) met this week to review more than eighty-nine grant submissions ... experienced and emerging young scientists in the Parkinson’s field.     , The American Parkinson ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) ... House on May 4, would result in 23 million Americans losing their health insurance ... 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear from ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using ... Viewers can reconnect with America as it explores some of the best places to ... for an inventive new place for a family vacation, and have discovered hiking. Many ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/10/2017)... , May 10, 2017 CSSi, the ... for the clinical research industry, is proud to announce ... . The new website features both enriched content and ... experience and enhances the company,s already well-established position as ... "After many months of hard work, ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology: